Answers are grounded in this paper and cite their sources.
Treating patients with end-stage organ failure is ideally achieved through organ transplantation, but long-term reliance on non-specific immunosuppressants post-operatively easily leads to systemic toxicity and chronic graft rejection. In recent years, inducing specific immune tolerance using regulatory T cells (Tregs) has become a research hotspot, but the instability of Treg function in vivo and the lack of precise targeting remain unresolved research gaps. This article systematically analyzes the mechanism of action of Tregs in controlling organ transplant immune rejection, and explores their isolation and purification standards and cutting-edge infusion protocols. Simultaneously, it focuses on the innovative application of targeted nanodelivery technology (such as targeting the CD248 biomarker) to optimize Treg expression. The results show that precise targeted intervention can significantly increase the number of Treg cells in the graft, prolong the survival time of the allogeneic organ, and effectively reduce dependence on traditional immunosuppressive drugs. This analysis provides valuable reference for improving the prognosis of transplant patients using specific cell therapy. Although current challenges such as limited clinical research samples and difficulties in in vivo tracking remain unresolved, it is believed that future research will further explore targeted biomarkers and the timing of administration, comprehensively promoting the clinical translation of Treg therapy.
No takes yet. Share an insight, caveat, or question.
Zhouboyan Wei (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: